Inflammation and tumor progression: signaling pathways and targeted intervention

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: July 12, 2021

Abstract Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses tumor progression, potentially displaying opposing effects on therapeutic outcomes. Chronic inflammation facilitates progression treatment resistance, whereas induction of acute inflammatory reactions often stimulates the maturation dendritic cells (DCs) antigen presentation, leading anti-tumor immune responses. In addition, multiple signaling pathways, such as nuclear factor kappa B (NF-kB), Janus kinase/signal transducers activators transcription (JAK-STAT), toll-like receptor (TLR) cGAS/STING, mitogen-activated protein kinase (MAPK); factors, including cytokines (e.g., interleukin (IL), interferon (IFN), necrosis (TNF)-α), chemokines C-C motif chemokine ligands (CCLs) C-X-C (CXCLs)), growth factors vascular endothelial (VEGF), transforming (TGF)-β), inflammasome; well metabolites prostaglandins, leukotrienes, thromboxane, specialized proresolving mediators (SPM), have been identified pivotal regulators initiation resolution inflammation. Nowadays, local irradiation, recombinant cytokines, neutralizing antibodies, small-molecule inhibitors, DC vaccines, oncolytic viruses, TLR agonists, SPM developed specifically modulate in cancer therapy, with some these already undergoing clinical trials. Herein, we discuss crosstalk between processes. We also highlight potential targets for harnessing cancer.

Language: Английский

---

Detection of immunogenic cell death and its relevance for cancer therapy

Cell Death and Disease, Journal Year: 2020, Volume and Issue: 11(11)

Published: Nov. 26, 2020

Abstract Chemotherapy, radiation therapy, as well targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by exposure release numerous damage-associated molecular patterns (DAMPs), altogether confer a robust adjuvanticity dying cancer cells, they favor recruitment activation antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) secreted ATP, annexin A1 (ANXA1), type I interferon, high-mobility group box 1 (HMGB1). Additional hallmarks ICD encompass phosphorylation eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known eIF2α), autophagy, global arrest in transcription translation. Here, we outline methodological approaches for measuring markers vitro ex vivo discovery next-generation antineoplastic agents, development personalized regimens, identification optimal therapeutic combinations clinical management cancer.

Language: Английский

---

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: June 20, 2022

Abstract In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors respond poorly or even not ICIs, partly caused absence of tumor-infiltrating lymphocytes (TILs), significantly limits application ICIs. Converting these “cold” into “hot” may ICIs is an unsolved question immunotherapy. Since it a general characteristic cancers resist apoptosis, induction non-apoptotic regulated cell death (RCD) emerging as new treatment strategy. Recently, several studies have revealed interaction between RCD and antitumor immunity. Specifically, autophagy, ferroptosis, pyroptosis, necroptosis exhibit synergistic responses while possibly exerting inhibitory effects on responses. Thus, targeted therapies (inducers inhibitors) against combination with exert potent activity, resistant This review summarizes multilevel relationship immunity RCD, including necroptosis, potential targeting improve efficacy malignancy.

Language: Английский

---

Neoantigens: promising targets for cancer therapy

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Jan. 6, 2023

Abstract Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by cells as a result various tumor-specific alterations, such genomic mutation, dysregulated RNA splicing, disordered post-translational modification, integrated viral open reading frames. recognized non-self trigger an immune response that is not subject to central peripheral tolerance. The quick identification prediction neoantigens been made possible advanced next-generation sequencing bioinformatic technologies. Compared tumor-associated antigens, highly immunogenic provide emerging targets personalized serve prospective predictors survival prognosis checkpoint blockade responses. therapies will be aided understanding mechanism underlying neoantigen-induced anti-tumor streamlining process neoantigen-based immunotherapies. This review provides overview on characterization outlines clinical applications immunotherapeutic strategies based neoantigens. We also explore their current status, inherent challenges, translation potential.

Language: Английский

---

Immune checkpoint therapy—current perspectives and future directions

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1652 - 1669

Published: April 1, 2023

Language: Английский

---

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Advanced Science, Journal Year: 2022, Volume and Issue: 9(22)

Published: June 2, 2022

Abstract Tumor immunotherapy is only effective in a fraction of patients due to low response rate and severe side effects, these challenges clinics can be addressed through induction immunogenic cell death (ICD). ICD elicited from many antitumor therapies release danger associated molecular patterns (DAMPs) tumor‐associated antigens facilitate maturation dendritic cells (DCs) infiltration cytotoxic T lymphocytes (CTLs). The process reverse the tumor immunosuppressive microenvironment improve sensitivity immunotherapy. Nanostructure‐based drug delivery systems (NDDSs) are explored induce by incorporating therapeutic molecules for chemotherapy, photosensitizers (PSs) photodynamic therapy (PDT), photothermal conversion agents (PTT), radiosensitizers radiotherapy (RT). These NDDSs loaded at right dose place time, resulting greater effectiveness lower toxicity. Immunotherapeutic also combined with achieve synergic effect multi‐modality approach. In this review, harnessed load multiple PDT, PTT, RT combination promote reduce effects cancer treatment.

Language: Английский

---

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: July 29, 2022

Abstract Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic effect on remote and non-irradiated tumor deposits, which called abscopal effect. The view RT as a simple treatment has dramatically changed in recent years, it now widely accepted that provoke immune response gives strong rationale the combination immunotherapy (iRT). Nevertheless, several points remain to be addressed such interaction system, identification best schedules with (IO), expansion mechanism amplify iRT. To answer these crucial questions, we roundly summarize underlying showing whole landscape clinical trials attempt identify In consideration rarity effect, propose occurrence induced by radiation promoted 100% molecular genetic level. Furthermore, “radscopal effect” refers using low-dose reprogram microenvironment may overcome resistance Taken together, could regarded trigger antitumor response, help IO used radical added into current standard regimen patients metastatic cancer.

Language: Английский

---

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(5), P. 261 - 279

Published: Jan. 19, 2021

Language: Английский

---

Immunotherapy in colorectal cancer: current achievements and future perspective

International Journal of Biological Sciences, Journal Year: 2021, Volume and Issue: 17(14), P. 3837 - 3849

Published: Jan. 1, 2021

Following dramatic success in many types of advanced solid tumors, interest immunotherapy for the treatment colorectal cancer (CRC) is increasingly growing. Given compelling long-term durable remission, two programmed cell death 1 (PD-1)-blocking antibodies, pembrolizumab and nivolumab (with or without Ipilimumab), have been approved patients with metastatic (mCRC) that mismatch-repair-deficient microsatellite instability-high (dMMR-MSI-H). Practice-changing results several randomized controlled trials to move into first-line MSI-H metastasis earlier stage were reported successively past 2 years. Besides, new intriguing advances expand efficacy mCRC mismatch-repair-proficient low instability (pMMR-MSI-L) demonstrated potential benefits vast majority cases. Great attention also paid vaccines adoptive therapy (ACT). In this review, we summarize above progresses, highlight current predictive biomarkers responsiveness broad clinical utility.

Language: Английский

---

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Journal for ImmunoTherapy of Cancer, Journal Year: 2021, Volume and Issue: 9(7), P. e002591 - e002591

Published: July 1, 2021

With the broad application of cancer immunotherapies such as immune checkpoint inhibitors in multiple types, immunological landscape tumor microenvironment (TME) has become enormously important for determining optimal treatment. Tumors can be immunologically divided into two categories: inflamed and non-inflamed based on extent cell infiltration their activation status. In general, are preferable tumors than tumors. Regulatory T cells (Tregs), an immunosuppressive subset CD4 + cells, play essential role maintaining self-tolerance homeostasis. immunity, Tregs compromise surveillance against healthy individuals impair antitumor response tumor-bearing hosts. Tregs, therefore, accelerate evasion by leading to development progression various types cancer. Therefore, considered a crucial therapeutic target immunotherapy. Abundant observed TME many cancer, both Diverse mechanisms Treg accumulation, activation, survival have been uncovered different indicating importance understanding mechanism each patient when selecting Treg-targeted therapy. Here, we review recent advances abundance optimize Furthermore, addition conventional strategies targeting surface molecules predominantly expressed reagents signaling pathways specifically employed infiltration, type illustrated novel therapies. The effectiveness precision therapy depends conditions patient.

Language: Английский

---